Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Takeaways: Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentiall...
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
